Cash, cash equivalents and marketable securities as of March 31 were $863.0M. This cash position does not include the additional $31.3M received in April from the tavapadon risk-sharing arrangement. Cerevel’s cash, cash equivalents, and marketable securities are expected to support seven data readouts in 2024 and fund operations into 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
- Billionaire Joseph Edelman Snaps Up These 2 Biotech Stocks — Here’s Why You Should Follow
- Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Cerevel holder Perceptive amends filing, says not in ‘strategic’ deal talks